Conference Coverage

Intranasal naloxone promising for type 1 hypoglycemia

 

Key clinical point: Intranasal naloxone might be just the ticket to prevent hypoglycemia-associated autonomic failure in type 1 diabetes mellitus.

Major finding: Overall, there was no difference in peak epinephrine levels between the first day 1 hypoglycemic episode and the third episode on day 2 in subjects randomized to naloxone (942 plus or minus 190 pg/mL versus 857 plus or minus 134 pg/mL; P = 0.4).

Study details: Randomized trial with seven healthy volunteers

Disclosures: There was no industry funding for the work, and the investigators didn’t have any disclosures.

Source: Aleksic S et al. ADA 2018, Abstract 10-LB


 

REPORTING FROM ADA 2018

The study subjects were men, 43 years old, on average, with a mean body mass index of 26 kg/m2.

The investigators didn’t have any disclosures, and there was no industry funding for the work.

SOURCE: Aleksic S et al. ADA 2018, Abstract 10-LB.

Next Article:

   Comments ()